Outcomes and risk factors for mortality in community-onset bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy

References

• Cheong HS, Kang CI, Kwon KT, Heo ST, Wi YM, Kim ES, et al. Clinical significance of healthcare-associated infections in community-onset Escherichia coli bacteraemia. J Antimicrob Chemother 2007;60:1355–60.
   PubMed Web of Science ®Google Scholar
• Ortega M, Marco F, Soriano A, Almela M, Martinez JA, Munoz A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568–74.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta- lactamases: a clinical update. Clin Microbiol Rev 2005;18: 657–86.
   PubMed Web of Science ®Google Scholar
• Cheong HS, Ko KS, Kang CI, Chung DR, Peck KR, Song JH. Prevalence of extended-spectrum beta-lactamase among Enterobacteriaceae blood isolates with inducible AmpC beta-lactamase. Infect Chemother 2010;42:280–4.
   Google Scholar
• Arpin C, Dubois V, Coulange L, Andre C, Fischer I, Noury P, et al. Extended-spectrum beta-lactamase- producing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother 2003;47: 3506–14.
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004;48:4574–81.
   PubMed Web of Science ®Google Scholar
• Azap OK, Arslan H, Serefhanoglu K, Colakoglu S, Erdogan H, Timurkaynak F, et al. Risk factors for extended-spectrum beta-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin Microbiol Infect 2010;16:147–51.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Rodriguez-Bano J, Arslan H, Pitout JD, Quentin C, Calbo ES, et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009;49:682–90.
   PubMed Web of Science ®Google Scholar
• Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57:780–3.
   PubMed Web of Science ®Google Scholar
• Kang CI, Song JH, Chung DR, Peck KR, Ko KS, Yeom JS, et al. Risk factors and treatment outcomes of community-onset bacteraemia caused by extended-spectrum beta- lactamase-producing Escherichia coli. Int J Antimicrob Agents 2010;36:284–7.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Hanson ND, Church DL, Laupland KB. Population-based laboratory surveillance for Escherichia coli- producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis 2004;38:1736–41.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005;56:52–9.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Alcala JC, Cisneros JM, Grill F, Oliver A, Horcajada JP, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med 2008;168:1897–902.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Picon E, Gijon P, Hernandez JR, Ruiz M, Pena C, et al. Community-onset bacteremia due to extended- spectrum beta-lactamase-producing Escherichia coli : risk factors and prognosis. Clin Infect Dis 2010;50:40–8.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, de Cueto M, Rios MJ, et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407–14.
   PubMed Web of Science ®Google Scholar
• Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791–7.
   PubMed Web of Science ®Google Scholar
• Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005;49:760–6.
   PubMed Web of Science ®Google Scholar
• Kim J, Lim YM, Jeong YS, Seol SY. Occurrence of CTX-M-3, CTX-M-15, CTX-M-14, and CTX-M-9 extended-spectrum beta-lactamases in Enterobacteriaceae clinical isolates in Korea. Antimicrob Agents Chemother 2005;49:1572–5.
   PubMed Web of Science ®Google Scholar
• Kim J, Lim YM, Rheem I, Lee Y, Lee JC, Seol SY, et al. CTX-M and SHV-12 beta-lactamases are the most common extended-spectrum enzymes in clinical isolates of Escherichia coli and Klebsiella pneumoniae collected from 3 university hospitals within Korea. FEMS Microbiol Lett 2005;245:93–8.
   PubMed Web of Science ®Google Scholar
• Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913–20.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006;50:498–504.
   PubMed Web of Science ®Google Scholar
• Kang CI, Chung DR, Ko KS, Peck KR, Song JH. Risk factors for mortality and impact of broad-spectrum cephalosporin resistance on outcome in bacteraemic intra-abdominal infections caused by Gram-negative bacilli. Scand J Infect Dis 2011;43:202–8.
   PubMedGoogle Scholar
• Joo EJ, Kang CI, Ha YE, Park SY, Kang SJ, Wi YM, et al. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection. Infection 2011;39:309–18.
   PubMed Web of Science ®Google Scholar
• Cheong HS, Kang CI, Lee JA, Moon SY, Joung MK, Chung DR, et al. Clinical significance and outcome of nosocomial acquisition of spontaneous bacterial peritonitis in patients with liver cirrhosis. Clin Infect Dis 2009;48:1230–6.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. beta-Lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012;54:167–74.
   PubMed Web of Science ®Google Scholar
• Kang CI, Park SY, Chung DR, Peck KR, Song JH. Piperacillin–tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect 2012;64:533–4.
   PubMed Web of Science ®Google Scholar